Clinical documentation has quietly become one of the best-funded categories in healthcare AI. The numbers, as publicly reported, are striking: Abridge has raised on the order of $800 million, with a mid-2025 Series E reportedly valuing the company at $5.3 billion. Ambience Healthcare closed a $243 million Series C at a reported $1.25 billion valuation. Suki has raised roughly $70 million across rounds and reports deployments in hundreds of health systems.
The anchor for the whole category remains Microsoft's acquisition of Nuance — a $19.7 billion transaction that put ambient clinical documentation at the centre of one of the largest healthcare software deals ever made.
Where the revenue is
Industry analyses put ambient scribe revenue at roughly $600 million in 2025, more than doubling year on year. Almost all of it comes from one motion: enterprise sales into large US health systems, integrated with the major electronic health records, closed by sales teams over long procurement cycles.
The gap the money ignores
Every dollar above is optimised for a doctor who works inside a hospital that buys software on their behalf. The doctor who buys with their own card — the private-practice specialist, the solo clinician, the doctor whose hospital will not approve a scribe for another two years — is served by almost none of it. In markets like India, where most consultations happen outside any EHR at all, the category's core assumptions simply do not apply.
That gap is not a rounding error. It is most of the world's doctors.